Amgen (NQ:AMGN)

GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle

September 19, 2025

The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like...

Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug ↗

How Is The Market Feeling About Amgen? ↗

September 17, 2025

Via Benzinga

September 03, 2025

Via Stocktwits

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

European Medicines Agency's panel recommends expanding Amgen's Uplizna to treat IgG4-related disease, with trial data showing reduced flares and higher remission rates.

EMA Backs Amgen Drug For Rare Autoimmune Disorder ↗

September 19, 2025

Via Benzinga

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗

September 19, 2025

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.

Via Chartmill

Uncover the latest developments among S&P500 stocks in today's session. ↗

September 19, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health

September 15, 2025

The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor...

These drugmakers have competitive yields and have increased their dividends at a good clip.

2 Healthcare Dividend Stocks to Buy and Hold ↗

September 14, 2025

The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment

Topics Intellectual Property

September 12, 2025

The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Topics Artificial Intelligence Bankruptcy Economy

1 Cash-Producing Stock to Target This Week and 2 Facing Challenges

September 11, 2025

Amgen and Kyowa Kirin report positive interim results for rocatinlimab, showing long-term safety and sustained efficacy in moderate to severe atopic dermatitis patients.

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis ↗

September 09, 2025

Via Benzinga

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

September 09, 2025

From Kyowa Kirin

Via GlobeNewswire

If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today ↗

September 08, 2025

You could have done worse -- or much better.

Nvidia's $600M investment in Quantinuum highlights quantum computing's commercial evolution and may prompt new ETF strategies in the coming years.

Topics Economy

Nvidia Just Went Quantum—And ETFs Are Scrambling To Catch Up ↗

September 04, 2025

Via Benzinga

Topics ETFs

Why Is Sanofi Stock Falling Thursday? ↗

September 04, 2025

William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential.

Via Benzinga

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug ↗

September 04, 2025

Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results.

Via Benzinga

2 Safe-and-Steady Stocks to Keep an Eye On and 1 Facing Challenges

September 03, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

2 Profitable Stocks Worth Your Attention and 1 We Avoid

September 01, 2025

These stocks offer more than just dividends.

2 Dividend Stocks to Hold for the Next 10 Years ↗

August 28, 2025

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Topics Economy

2 Large-Cap Stocks to Target This Week and 1 That Underwhelm

August 28, 2025

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up ↗

Deep Dive Into Amgen Stock: Analyst Perspectives (9 Ratings) ↗

August 25, 2025

Via Benzinga

August 25, 2025

BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen.

Via Benzinga

3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade ↗

August 20, 2025

Some of the highest-yielding stocks in the Dow Jones Industrial Average index look like smart buys for income-seeking investors.

The Dow Jones (^DJI) includes some of the most reliable stocks in the market, and while not all are equal, a few continue to shine. These companies are leveraging their strengths to maintain leadership...

Topics Stocks

3 Dow Jones Stocks to Keep an Eye On

August 20, 2025

Warren Buffett, Cathie Wood Share 2 Stock Investments In Common: Can You Guess What They Are? ↗

Topics Artificial Intelligence Stocks

August 18, 2025

Cathie Wood looks for growth and companies on their way to big profits. Warren Buffett prefers looking for value and consistent profits. The two investors have two stock investments in common.

Via Benzinga

Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS ↗

August 16, 2025

Greenlight Capital, led by David Einhorn, has disclosed its Q2 2025 13F filing trades.

Via Benzinga

Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet. ↗

August 16, 2025

Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath.